AGAlison Grazioli

Alison Grazioli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alison Grazioli has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Janhavi Athale

    Department of Medicine University of Maryland School of Medicine Program in Trauma Baltimore Maryland USA

    3 shared publications
  • Joseph Rabin

    Department of Surgery and Program in Trauma, R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD

    3 shared publications
  • Mark T. Gladwin

    Department of Medicine, University of Maryland School of Medicine, Baltimore, USA

    3 shared publications
  • Ronson J. Madathil

    Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA

    3 shared publications
  • Bartley P. Griffith

    Cardiothoracic Surgery University of Maryland School of Medicine Baltimore Maryland USA

    2 shared publications
  • Bradley S. Taylor

    Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD

    2 shared publications

Latest Publications

  • Open Access

    Noninvasive Monitoring of Complement Using the Bioluminescent Modified Ham Assay in the Second Porcine‐to‐Human Live Heart Transplant

    by Michael A. Cole, Andy Tully, Javier Galindo, Avneesh K. Singh, Meryl Waldman, Janhavi Athale, Idris Boudhabhay, Erwan Morgand, Fariza Mezine, Valentin Goutaudier, et al.

    Complement activation is a major barrier to xenotransplantation. We report detailed complement monitoring in a 58‐year‐old man who received a 10 gene–edited porcine heart expressing human complement regulators CD46 and CD55. Despite these transgenes and prophylactic systemic complement inhibition with C1 esterase inhibitor (C1INH), early surveillance biopsy on post‐operative day (POD) 13 showed significant histologic evidence of complement deposition with C3d and C4d within capillaries and endothelial activation. In light of these findings, treatment was escalated to terminal complement inhibition using eculizumab. Post‐operative complement activity was assessed via immunohistochemistry and dynamic ex vivo serum assays, including a novel bioluminescent modified Ham (bmHam) assay. Following eculizumab initiation, serum sC5b‐9 dropped to undetectable levels, and bmHam cytotoxicity decreased significantly, confirming terminal pathway inhibition. Dilutional bmHam assays further demonstrated stronger complement blockade with eculizumab than with C1INH. However, repeat transplant biopsy on POD 30 biopsy showed persistence of anti‐C4d+ and anti‐C3c+ staining, and increased C5b‐9 compared to POD13. This breakthrough was identified by the dilutional bmHam but was not detected by changes in CH50 or sC5b‐9. These findings highlight the potential need for early terminal complement inhibition and integrated functional monitoring as critical components of xenotransplant management.


  • Open Access

    Outcomes and survival prediction in adults with sickle cell disease treated with extracorporeal membrane oxygenation

    by Alison Grazioli, Michael Plazak, Kate Willsey, Joseph Rabin, Raymond P. Rector, Leonid Belyayev, Allison S. Lankford, Thomas M. Scalea, Aakash Shah, Bradley S. Taylor, et al.

    The utility of extracorporeal membrane oxygenation (ECMO) support for adult patients with sickle cell disease (SCD) remains poorly understood. We aimed to characterize a cohort of adult individuals with SCD in the Extracorporeal Life Support Organization (ELSO) registry who underwent venoarterial (VA) or venovenous (VV) ECMO treatment, assess clinical outcomes, and determine predictors of mortality. This multicenter, retrospective study evaluated in-hospital mortality and clinical outcomes such as bleeding and thrombotic events (BTEs) of adult patients in the ELSO registry with SCD–associated International Classification of Diseases, 9th and 10th Revision, Clinical Modification codes. Post hoc multivariable logistic regression model was developed assessing predictors of mortality. Of 206 included patients, 126 and 80 received cannulation for VA ECMO or VV ECMO, respectively. Eighty-three patients (40.3%) were discharged alive; in-hospital survival was 25.5% and 61.1% for VA and VV ECMO, respectively (P < .001). BTEs were common during VA (45.6%) and VV (33.8%) ECMO support. There was significant increase in BTE incidence for nonsurvivors compared with survivors with VA ECMO (55.4% vs 26.5%; P < .001) and VV ECMO (58.1% vs 18.4%; P = .01). Male sex, increased age, pre–extracorporeal life support (ECLS) cardiac arrest, cannulation for extracorporeal cardiopulmonary resuscitation (eCPR), and elevated lactate were predictive of in-hospital mortality in the VA ECMO cohort. In conclusion, in adult patients with SCD, in-hospital survival was significantly lower with VA ECMO than VV ECMO. Male sex, increased age, eCPR support, elevated lactate, and pre-ECLS arrest were strongest indicators of VA ECMO mortality. Bleeding and thrombotic complications have an association with inpatient mortality for those treated with ECMO.


  • Open Access

    Understanding the Outcomes of Extracorporeal Membrane Oxygen Support in Patients With Sickle Cell Trait

    by Kate M. Willsey, Michael E. Plazak, Leonid Belyayev, Joseph Rabin, Janhavi Athale, Nancy Kim, Mark T. Gladwin, Alison Grazioli

    The impact of common hemoglobinopathies, such as sickle cell trait (SCT), on outcomes in adults requiring extracorporeal membrane oxygenation (ECMO) remains understudied. Extracorporeal Life Support Organization registry data was analyzed to assess outcomes of adults with SCT or sickle cell disease (SCD) who underwent venoarterial or venovenous ECMO. Among 215 patients identified, 49 had SCT and 166 had SCD. The prevalence of SCT appeared grossly underestimated. Age-adjusted survival rates for SCT patients were favorable compared with those with SCD for venoarterial (43.5% vs. 19.5%; p = 0.04) and venovenous (73.3% vs. 44.8%; p = 0.11) ECMO. Bleeding and thrombotic event rates and renal complications in SCT patients were comparable to those with SCD and similar to reported rates in general adult ECMO populations. While our findings suggest that ECMO may be safely used in patients with SCT, further investigation is essential to determine the clinical impact of sickle cell and other hemoglobinopathies on ECMO therapy.

  • Use of High-dose Intravenous Immunoglobulin as Initial Therapy for Heparin-induced Thrombocytopenia in Patients With High Bleeding Risk

    by Alison V. Grazioli, Michael E. Plazak, Cynthia S. Shen, Thomas M. Scalea, Rishi Kundi, Ramon A. Riojas, Leonid A. Belyayev


  • Open Access

    Venoarterial Extracorporeal Membrane Oxygenation Therapy in Patients with Sickle Cell Disease: Case Series and Review for Intensive Care Physicians

    by Alison Grazioli, Joseph Rabin, Raymond P. Rector, Zhongjun J. Wu, Allen P. Burke, Nima Sharifai, Aakash Shah, Bradley S. Taylor, Mark T. Gladwin

    Sickle cell disease (SCD) is associated with substantial morbidity and early mortality in afflicted adults. Cardiopulmonary complications that occur at increased frequency in SCD such as pulmonary embolism, pulmonary arterial hypertension, and acute chest syndrome can acutely worsen right ventricular function and lead to cardiogenic shock. Mechanical circulatory support including venoarterial extracorporeal membrane oxygenation (VA ECMO) is being increasingly utilized to treat hemodynamic collapse in various patient populations. However, a paucity of literature exists to guide the use of mechanical circulatory support in adults with SCD where disease-related sequela and unique hematologic aspects of this disorder may complicate extracorporeal therapy and must be understood. Here, we review the literature and describe three cases of adult patients with SCD who developed cardiogenic shock from acute decompensated right heart failure and were treated clinically with VA ECMO. Using an in vitro ECMO system, we investigate a potential increased risk of systemic fat emboli in patients with SCD who may be experiencing vaso-occlusive events with bone marrow involvement given the high-volume shunting of blood from venous to arterial systems with VA ECMO. The purpose of this study is to describe available extracorporeal life support experiences, review potential complications, and discuss the special considerations needed to further our understanding of the utility of VA ECMO in those with SCD.


  • Open Access

    Pulmonary Co-Infections Detected Premortem Underestimate Postmortem Findings in a COVID-19 Autopsy Case Series

    by Andrew P. Platt, Benjamin T. Bradley, Nadia Nasir, Sydney R. Stein, Sabrina C. Ramelli, Marcos J. Ramos-Benitez, James M. Dickey, Madeleine Purcell, Shreya Singireddy, Nicole Hays, et al.

    Bacterial and fungal co-infections are reported complications of coronavirus disease 2019 (COVID-19) in critically ill patients but may go unrecognized premortem due to diagnostic limitations. We compared the premortem with the postmortem detection of pulmonary co-infections in 55 fatal COVID-19 cases from March 2020 to March 2021. The concordance in the premortem versus the postmortem diagnoses and the pathogen identification were evaluated. Premortem pulmonary co-infections were extracted from medical charts while applying standard diagnostic definitions. Postmortem co-infection was defined by compatible lung histopathology with or without the detection of an organism in tissue by bacterial or fungal staining, or polymerase chain reaction (PCR) with broad-range bacterial and fungal primers. Pulmonary co-infection was detected premortem in significantly fewer cases (15/55, 27%) than were detected postmortem (36/55, 65%; p < 0.0001). Among cases in which co-infection was detected postmortem by histopathology, an organism was identified in 27/36 (75%) of cases. Pseudomonas, Enterobacterales, and Staphylococcus aureus were the most frequently identified bacteria both premortem and postmortem. Invasive pulmonary fungal infection was detected in five cases postmortem, but in no cases premortem. According to the univariate analyses, the patients with undiagnosed pulmonary co-infection had significantly shorter hospital (p = 0.0012) and intensive care unit (p = 0.0006) stays and significantly fewer extra-pulmonary infections (p = 0.0021). Bacterial and fungal pulmonary co-infection are under-recognized complications in critically ill patients with COVID-19.


  • Open Access

    Maternal transfer of IgA and IgG SARS-CoV-2 specific antibodies transplacentally and via breast milk feeding

    by Mohammad M. Sajadi, Narjes Shokatpour, Madeleine Purcell, Zahra Rikhtegaran Tehrani, Allison Lankford, Allison Bathula, James D. Campbell, Elizabeth Adrianne Hammershaimb, Kristopher B. Deatrick, Casey Bor, et al.

    Background: Although there have been many studies on antibody responses to SARS-CoV-2 in breast milk, very few have looked at the fate of these in the infant, and whether they are delivered to immunologically relevant sites in infants. Methods: Mother/infant pairs (mothers who breast milk fed and who were SARS-CoV-2 vaccinated before or after delivery) were recruited for this cross-sectional study. Mother blood, mother breast milk, infant blood, infant nasal specimen, and infant stool was tested for IgA and IgG antibodies against SARS-CoV-2 spike trimer. Results: Thirty-one mother/infant pairs were recruited. Breast milk fed infants acquired systemic anti-spike IgG antibodies only if their mothers were vaccinated antepartum (100% Antepartum; 0% Postpartum; P<0.0001). Breast milk fed infants acquired mucosal anti-spike IgG antibodies (in the nose) only if their mothers were vaccinated antepartum (89% Antepartum; 0% Postpartum; P<0.0001). None of the infants in either group had anti-spike IgA in the blood. Surprisingly, 33% of the infants whose mothers were vaccinated antepartum had high titer anti-spike IgA in the nose (33% Antepartum; 0% Postpartum; P = 0.03). Half-life of maternally transferred plasma IgG antibodies in the Antepartum infant cohort was ~70 days. Conclusion: Vaccination antepartum followed by breast milk feeding appears to be the best way to provide systemic and local anti-SARS-CoV-2 antibodies for infants. The presence of high titer SARS-CoV-2-specific IgA in the nose of infants points to the potential importance of breast milk feeding early in life for maternal transfer of mucosal IgA antibodies. Expectant mothers should consider becoming vaccinated antepartum and consider breast milk feeding for optimal transfer of systemic and mucosal antibodies to their infants.


  • Open Access

    Cardiac surgery in acute heparin-induced thrombocytopenia managed with therapeutic plasma exchange and intravenous immunoglobulin

    by Alison Grazioli, Noah P. Splinter, Michael E. Plazak, Bartley P. Griffith, Siamak Dahi, Allison H. Bathula, Nora H. Cheung, Anand Padmanabhan


  • The authors reply

    by Janhavi Athale, Alison Grazioli, Junfeng Sun